GLP-1 Mental Health Data in Teens

A new retrospective review offers a modest but useful data point on GLP-1 receptor agonists and mental health in adolescents with obesity. At one pediatric endocrinology center, researchers found no increase in suicidality screening results after young people started liraglutide or semaglutide. In the subgroup with paired depression questionnaires, scores were lower at follow-up. That is reassuring within this small sample. It does not show that these medicines improve mental health, and it cannot settle the broader safety question.^[1]

The practical reading is simple: this paper does not identify a short-term signal of increased suicidality in the patients it studied. It should not be read as a reason to self-start, stop, or change a prescribed medicine. Mental-health concerns, mood changes, or suicidal thoughts need prompt discussion with a qualified clinician or local emergency service.^[1]

What the researchers did

The paper is a retrospective chart review. That means the team looked back through existing medical records rather than assigning treatment in a randomized trial. It included 44 adolescents and young adults aged 12 to 21 with obesity who received liraglutide or semaglutide at one academic center between June 2022 and December 2024.^[1]

At clinic visits, the center used either the Patient Health Questionnaire-9, commonly called the PHQ-9, to screen depressive symptoms, or the Ask Suicide-Screening Questions tool, called ASQ, to screen suicidality. The authors limited their comparisons to patients who had the same screening instrument at baseline and follow-up. That detail matters: the headline sample of 44 is not the same as the paired groups used for each result.^[1]

What it found

Fifteen participants had paired PHQ-9 results. Their median score fell from 6 at baseline to 1 at follow-up, a difference the authors reported as statistically significant. The paper says this change was independent of BMI change. Twenty-three participants had paired ASQ data; the authors reported no increase in suicidality and no new suicidal ideation in that group.^[1]

Those are findings about screening results in a selected clinical cohort, not a diagnosis of depression or a proof that GLP-1 treatment caused a mood benefit. A lower questionnaire score can have many explanations, including changes in care, life circumstances, or which patients returned for follow-up. The study was not designed to separate those possibilities.^[1]

Why the label context matters

GLP-1 receptor agonist is the class name for medicines that act at the GLP-1 receptor, a signaling pathway involved in appetite and glucose regulation. Semaglutide is one member of that class. In the United States, the current WEGOVY injection label includes long-term weight-management use for pediatric patients aged 12 years and older with obesity, alongside diet and physical-activity measures.^[2]

The same current label records that its suicidal behavior and ideation warning section was removed in February 2026. A label change is not a guarantee that every individual will have the same experience, and it does not make a small chart review definitive. It does show why the question needs to be read through current evidence and current labeling, not through a single social-media claim or an older warning alone.^[2]

What this study cannot answer

The authors describe the review as small and exploratory, and they call for larger prospective case-control studies. It was conducted at one center, did not use a randomized comparison group, and relied on the patients with paired screening data. Those limits make it unsuitable for estimating rare outcomes or proving that a medicine changes depression risk in the wider adolescent population.^[1]

It also groups liraglutide and semaglutide together. That is reasonable for a class-focused safety question, but it cannot provide a separate, precise estimate for each medicine. Readers looking at the specific evidence and regulatory context for semaglutide should keep that distinction in view.^[1]

What families can take from it

The study adds a cautious short-term observation: it did not detect increased suicidality screening results among the adolescents in this review. It does not replace individualized care. For a young person already using a GLP-1 medicine, questions about mood, behavior, sleep, appetite, or treatment burden belong in a conversation with the prescribing team. For urgent concerns about self-harm or suicidal thoughts, seek immediate help through local emergency services or a crisis service.^[1]

The broader lesson is about scale. One 44-person chart review can point researchers toward a question worth studying. It cannot give families a universal mental-health forecast. We need larger, prospective studies that follow young people for longer and report outcomes clearly enough to separate medicine effects from the rest of their clinical care.^[1]

What we do not yet know

We do not yet know whether the observed questionnaire changes would persist in a larger and more varied adolescent population. We do not know whether they would look the same with each GLP-1 medicine, after longer follow-up, or compared with matched young people receiving other obesity care. The paper raises no short-term safety alarm in its own cohort. It leaves those larger questions open.^[1]

For background on the medicine named most often in this coverage, see our semaglutide guide. It explains the drug's status and evidence base, but it is not a substitute for a clinician who knows an individual young person's medical and mental-health history.